Condition
EGFR Amplification
Total Trials
4
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 1 (1)
P 2 (1)
Trial Status
Completed2
Unknown1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04429542Phase 1Recruiting
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
NCT05290441Not ApplicableCompleted
Evaluation of Postmortem Pulmonary Interstitial Fibrosis Severity and EGFR Positivity in Covid-19 Pneumonia
NCT06022276Not ApplicableUnknown
Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors
NCT03618667Phase 2Completed
GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification
Showing all 4 trials